BR112023014723A2 - Compostos moduladores de gcn2 e usos dos mesmos - Google Patents

Compostos moduladores de gcn2 e usos dos mesmos

Info

Publication number
BR112023014723A2
BR112023014723A2 BR112023014723A BR112023014723A BR112023014723A2 BR 112023014723 A2 BR112023014723 A2 BR 112023014723A2 BR 112023014723 A BR112023014723 A BR 112023014723A BR 112023014723 A BR112023014723 A BR 112023014723A BR 112023014723 A2 BR112023014723 A2 BR 112023014723A2
Authority
BR
Brazil
Prior art keywords
gcn2
modulator compounds
compounds
modulating
diseases
Prior art date
Application number
BR112023014723A
Other languages
English (en)
Inventor
Benjamin Rahemtulla
Bradley Sherborne
G Thomson Christopher
P A Talbot Eric
J Mulvihill Mark
Savithri Ramurthy
Original Assignee
Hibercell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hibercell Inc filed Critical Hibercell Inc
Publication of BR112023014723A2 publication Critical patent/BR112023014723A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
  • Holo Graphy (AREA)

Abstract

compostos moduladores de gcn2 e usos dos mesmos. são providos aqui compostos, composições e métodos utilizáveis para modular a atividade de gcn2 e para tratar condições, doenças e distúrbios relacionados (por exemplo, câncer e doenças neurodegenerativas).
BR112023014723A 2021-01-22 2022-01-21 Compostos moduladores de gcn2 e usos dos mesmos BR112023014723A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163140314P 2021-01-22 2021-01-22
PCT/US2022/013383 WO2022159746A1 (en) 2021-01-22 2022-01-21 Gcn2 modulating compounds and uses thereof

Publications (1)

Publication Number Publication Date
BR112023014723A2 true BR112023014723A2 (pt) 2023-10-03

Family

ID=80446635

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023014723A BR112023014723A2 (pt) 2021-01-22 2022-01-21 Compostos moduladores de gcn2 e usos dos mesmos

Country Status (13)

Country Link
US (1) US20240083897A1 (pt)
EP (1) EP4281182A1 (pt)
JP (1) JP2024504364A (pt)
KR (1) KR20240021143A (pt)
CN (1) CN117203206A (pt)
AU (1) AU2022210760A1 (pt)
BR (1) BR112023014723A2 (pt)
CA (1) CA3209124A1 (pt)
CO (1) CO2023010940A2 (pt)
IL (1) IL304611A (pt)
MX (1) MX2023008589A (pt)
PE (1) PE20240691A1 (pt)
WO (1) WO2022159746A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
WO2023230567A1 (en) * 2022-05-25 2023-11-30 Hibercell, Inc. Gcn2 modulator for treating cancer
WO2024077092A1 (en) * 2022-10-04 2024-04-11 Hibercell, Inc. Gcn2 inhibitor for treating metastases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1673343A4 (en) * 2003-10-08 2008-09-10 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
US8524707B2 (en) * 2008-12-19 2013-09-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
US20220388964A1 (en) * 2019-04-12 2022-12-08 Hibercell, Inc. (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions

Also Published As

Publication number Publication date
CA3209124A1 (en) 2022-07-28
IL304611A (en) 2023-09-01
CO2023010940A2 (es) 2023-12-11
US20240083897A1 (en) 2024-03-14
WO2022159746A1 (en) 2022-07-28
PE20240691A1 (es) 2024-04-10
JP2024504364A (ja) 2024-01-31
MX2023008589A (es) 2023-08-09
KR20240021143A (ko) 2024-02-16
AU2022210760A1 (en) 2023-09-07
CN117203206A (zh) 2023-12-08
EP4281182A1 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
BR112023014723A2 (pt) Compostos moduladores de gcn2 e usos dos mesmos
BR112021021754A2 (pt) Cicloalquilas substituídas como moduladoras da via de estresse integrada
PH12020551184A1 (en) Biaryl derivative, preparation method thereof and pharmaceutical application thereof
ECSP21086429A (es) Moduladores de la vía integrada del estrés
NZ750174A (en) Somatostatin modulators and uses thereof
ECSP21032861A (es) Moduladores de profármacos de la vía de estrés integrada
BRPI0516883A (pt) compostos e métodos para modulação da atividade de trombopoietina
WO2020163823A8 (en) Therapeutic agents and methods of treatment
NZ757081A (en) Somatostatin modulators and uses thereof
MD3740475T2 (ro) Procedeu de producere a modulatorilor somatostatinei
MX2020011234A (es) Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3).
MX2022014868A (es) Inhibidores de cxcr-2 para tratar trastornos.
BR112022010082A2 (pt) Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
ZA202210888B (en) Mtorc1 modulators and uses thereof
BR112023020781A2 (pt) Moduladores de cbl-b e usos dos mesmos
MX2023004870A (es) Moduladores de la via integrada del estres.
EP3808375A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER WITH CD300C EXPRESSION INHIBITOR OR ACTIVITY INHIBITOR
BR112021017820A2 (pt) Composições e métodos para modulação da atividade de complemento
MX2022003671A (es) Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades.
AU2020264106A8 (en) Small molecule bromodomain inhibitors and uses thereof
WO2023240253A3 (en) Modulators of tnf-alpha activity
EP3904518A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING TUT4/7 EXPRESSION MODULATOR
BR112023024465A2 (pt) Usos de um modulador de somatostatina para o tratamento de doença
WO2023278325A8 (en) Bifunctional compounds that degrade alk and uses thereof
CA3199014A1 (en) Combination therapy for the treatment of a liver disease